Goodwin Guides City Therapeutics on $99.5 Million Series B Financing

Professionals

Robert FredericksonCatherine MagazuKingsley L. TaftSimone WaterburyOrtal Ben AharonGozde GuckayaLily JohnsonBonnee NieLibby SousaAnikó Bouley, ACPKathryn A. Georgian

View PDF

The Life Sciences team advised City Therapeutics, Inc., on the completion of a $99.5 million Series B financing. Viking Global Investors and Sofinnova Investments participated in the financing as new investors, along with Casdin Capital and NYBC Ventures, joined by existing investors ARCH Venture Partners, Fidelity Management & Research Company, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures, AN Ventures, and other undisclosed investors. Proceeds will be used to advance City Therapeutics’ pipeline of RNAi therapeutics, accelerate the company’s next-generation RNAi engineering platform, and support business development activities.

City Therapeutics is a biopharmaceutical company harnessing its next-generation RNAi platform to improve and expand the reach of RNAi-based medicines. The company is building a pipeline of innovative RNAi therapeutics to make a significant impact for patients across multiple therapeutic areas. Co-founded by pioneering executives and scientists in RNAi, City Therapeutics is based in Cambridge, MA, and has raised over $230 million from leading life sciences investors.

The Goodwin team was led by Catherine Magazu, Libby Sousa, Bonnee Nie, and Kingsley Taft and included Lily Johnson Cardona, Robert Frederickson, Simone Waterbury, Ortal Ben Aharon, Gozde Guckaya, Kathryn Georgian, and Aniko Bouley.

For more information on the deal, please read the press release and see coverage from Fierce Biotech.

Goodwin Guides City Therapeutics on $99.5 Million Series B Financing

Related Content

Expanding Corporate Criminal Liability in the UK: Key Impacts and Considerations for Organisations and Investors

Alvotech’s BLA for Vedolizumab Biosimilar First to be Accepted by FDA

Chime Biologics and Daewoong Pharmaceutical Partner on Dupilumab Biosimilar

BIOSECURE Update – 1260H List Released

Supreme Court Declines to Review $220 Million Drug Pricing Judgment Against Eli Lilly

Boan Biotech Submits BLA to FDA for Two Denosumab Biosimilars

Polpharma and Tuteur Enter License for the Commercialization of a Biosimilar Targeting Autoimmune Diseases in Latin America

Samsung Bioepis Launches OPUVIZ in Europe

Goodwin Represents Parabilis Medicines in Strategic Collaboration With Regeneron Pharmaceuticals for Up to $2.3 Billion

Goodwin Advises Engitix on Strategic Collaboration With GSK for £44.5 Million Upfront and Up to £118 Million in Milestones

Goodwin Guides Parabilis Medicines on Upsized $770.5 Million Initial Public Offering and $75 Million Private Placement to Regeneron Pharmaceuticals

Goodwin Advises Incyte in Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding Incyte’s Hematology Portfolio into Bleeding Disorders

The Legal 500 US 2026 Recognizes 47 Goodwin Practices and 185 Lawyers

Goodwin Advises SonoThera on Oversubscribed $125 Million Series B Financing

Innovafeed is Scaling Up and Entering a New Growth Phase Backed by a €51 Million Funding Round

Goodwin Advises Nurix Therapeutics on Global Collaboration With Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg for $700 Million Upfront and Up to $2.3 Billion in Total

Life Sciences